Combination treatment for liver cancer that cannot be removed
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial combines three treatments: Y-90 radioembolization (targeted radiation to liver tumors), two immunotherapy drugs (durvalumab and tremelimumab), and a targeted oral drug (zanzalintinib) to see if this combination can shrink or control liver cancer that cannot be removed by surgery or transplant. It may be an option for people whose cancer has not spread beyond the liver and who have not had prior systemic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and weigh more than 66 pounds.
- You must have hepatocellular carcinoma (a type of liver cancer) that cannot be removed with surgery or transplant, and it must be at a stage called B or C according to the Barcelona Clinic Liver Cancer scale.
- Your liver function must be reasonably good (Child-Pugh class A or B7, but not a specific poor-risk subgroup).
- You must be able to undergo Y-90 radioembolization, based on a pre-test, and you must have at least 30% of your liver that is not affected by cancer.
- You must have a performance status of 0 or 1, meaning you are able to do most of your daily activities with little or no help.
- You should not have had prior Y-90 treatment or prior systemic (whole-body) therapy for your liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for liver cancer that cannot be removed by surgery. It uses a special radiation therapy called Y90 along with other drugs to see if they work better together.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
Hear when a new Locally Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.